The recently published association of a particular promoter variant of the GPx-3 (plasma glutathione peroxidase) gene with increased risk for arterial ischemic stroke in this journal 1 was the result of a long-duration research project. A set of linked polymorphisms in the promotor of the GPx-3 gene was described previously, and it was shown that carriers of a particular haplotype (H 2 ) had a 2-fold increase in risk of ischemic stroke compared with noncarriers. 2 The authors had, furthermore, analyzed the regulation of GPx-3 expression in a cultured cell system, identified a novel transcription start site and demonstrated that hypoxia was a strong transcriptional regulator of GPx-3 expression. 3 The interest of the research group in GPx-3 was raised by their initial discovery of decreased plasma glutathione peroxidase activity in familial childhood stroke. 4 The novel investigations extended these findings in several ways: 8 single nucleotide polymorphisms (SNP) were identified in the 5Јend flanking region as well as 8 promoter haplotypes. The association of the H 2 haplotype with an increased risk of arterial ischemic stroke (AIS) was demonstrated in an enlarged series of 123 young adults, compared with 123 control subjects. The association was confirmed in a second independent population with childhood stroke (82 patients and 82 control subjects). 1 These promising results lead us to analyze the GPx-3 promoter in 2 populations of young stroke patients (Ͻ50 years) in order to confirm these results in a replica study. The H 2 haplotype was tagged with the Ϫ65 T/C SNP as well as with the Ϫ927 T/C variant (the combination of Ϫ65C and Ϫ927C identifies the H 2 haplotype as well as the very rare H 7 and H 8 haplotypes). In contrast to the findings of Voetsch et al, our observations (Table) did not show an elevated prevalence of H 2 among patients.
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To the Editor:
The recently published association of a particular promoter variant of the GPx-3 (plasma glutathione peroxidase) gene with increased risk for arterial ischemic stroke in this journal 1 was the result of a long-duration research project. A set of linked polymorphisms in the promotor of the GPx-3 gene was described previously, and it was shown that carriers of a particular haplotype (H 2 ) had a 2-fold increase in risk of ischemic stroke compared with noncarriers. 2 The authors had, furthermore, analyzed the regulation of GPx-3 expression in a cultured cell system, identified a novel transcription start site and demonstrated that hypoxia was a strong transcriptional regulator of GPx-3 expression. 3 The interest of the research group in GPx-3 was raised by their initial discovery of decreased plasma glutathione peroxidase activity in familial childhood stroke. 4 The novel investigations extended these findings in several ways: 8 single nucleotide polymorphisms (SNP) were identified in the 5Јend flanking region as well as 8 promoter haplotypes. The association of the H 2 haplotype with an increased risk of arterial ischemic stroke (AIS) was demonstrated in an enlarged series of 123 young adults, compared with 123 control subjects. The association was confirmed in a second independent population with childhood stroke (82 patients and 82 control subjects). 1 These promising results lead us to analyze the GPx-3 promoter in 2 populations of young stroke patients (Ͻ50 years) in order to confirm these results in a replica study. The H 2 haplotype was tagged with the Ϫ65 T/C SNP as well as with the Ϫ927 T/C variant (the combination of Ϫ65C and Ϫ927C identifies the H 2 haplotype as well as the very rare H 7 and H 8 haplotypes). In contrast to the findings of Voetsch et al, our observations (Table) did not show an elevated prevalence of H 2 among patients.
Further subclassification of the patients according to stroke etiology yielded haplotype frequencies (H 2 ϩH 7 ϩH 8 ) of 12.1% (Heidelberg) and 10.4% (Brescia) for large vessel atherosclerosis and 12.5% and 9.8% for cardioembolism. Our data revealed higher prevalences of H 2 Our analysis of young stroke patients from 2 further populations did not confirm the finding of Voetsch et al that patients carry more often than healthy control subjects the GPx-3 promoter haplotype H 2 . Because of ethnic differences and differences in age at first stroke the populations are not perfectly comparable. Sample error might be a further reason for the discrepancy between our data and the published findings. Further studies of the GPx-3 promoter in larger populations of young stroke patients are warranted.
